

From the INTERNATIONAL BUREAU

## PCT

NOTIFICATION OF TRANSMITTAL  
OF COPIES OF TRANSLATION  
OF THE INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY  
(CHAPTER I OR CHAPTER II  
OF THE PATENT COOPERATION TREATY)  
(PCT Rules 44bis.3(c) and 72.2)

To:

KAWAMIYA, Osamu  
AOYAMA & PARTNERS  
IMP Building  
3-7, Shiromi 1-chome  
Chuo-ku, Osaka-shi  
Osaka 5400001  
JAPON



Date of mailing (day/month/year)  
28 September 2006 (28.09.2006)

Applicant's or agent's file reference  
665078

## IMPORTANT NOTIFICATION

International application No.  
PCT/JP2005/004098

International filing date (day/month/year)  
09 March 2005 (09.03.2005)

Applicant  
Kyoto University et al

## 1. Transmittal of the translation to the applicant.

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

## 2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

## 3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

**It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.**

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Masashi Honda

Facsimile No. +41 22 338 82 70

Facsimile No. +41 22 338 82 70

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 665078	<b>FOR FURTHER ACTION</b>		See item 4 below
International application No. PCT/JP2005/004098	International filing date ( <i>day/month/year</i> ) 09 March 2005 (09.03.2005)	Priority date ( <i>day/month/year</i> ) 09 March 2004 (09.03.2004)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant Kyoto University			

1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).
2. This REPORT consists of a total of 7 sheets, including this cover sheet.

In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.

3. This report contains indications relating to the following items:

<input checked="" type="checkbox"/>	Box No. I	Basis of the report
<input type="checkbox"/>	Box No. II	Priority
<input checked="" type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/>	Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input checked="" type="checkbox"/>	Box No. VI	Certain documents cited
<input type="checkbox"/>	Box No. VII	Certain defects in the international application
<input checked="" type="checkbox"/>	Box No. VIII	Certain observations on the international application

4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis.2).

Date of issuance of this report 19 September 2006 (19.09.2006)	
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No. +41 22 338 82 70	Authorized officer  Masashi Honda  e-mail: pt08@wipo.int

## PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

ΤΩ;

# **PCT** *TRANSLATION*

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

		Date of mailing (day/month/year)
Applicant's or agent's file reference <b>665078</b>		<b>FOR FURTHER ACTION</b> See paragraph 2 below
International application No. <b>PCT/JP2005/004098</b>	International filing date (day/month/year) <b>09.03.2005</b>	Priority date (day/month/year) <b>09.03.2004</b>
International Patent Classification (IPC) or both national classification and IPC		
Applicant <b>Kyoto University</b>		

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

## 2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220

Name and mailing address of the ISA/JP	Authorized officer
Facsimile No.	Telephone No.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2005/004098

Box No. 1 Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
 This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material  
 a sequence listing  
 table(s) related to the sequence listing
  - b. format of material  
 in written format  
 in computer readable form
  - c. time of filing/furnishing  
 contained in the international application as filed.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority for the purposes of search.
3.  In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/JP2005/004098

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application

claims Nos. 10-13

because:

the said international application, or the said claims Nos. 10-13

relate to the following subject matter which does not require an international preliminary examination (specify):

The inventions of claims 10-13 relate to a method for treatment of the human body by therapy, which does not require an international preliminary examination in accordance with PCT Rule 67.1(iv).

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_\_\_\_\_ are so unclear that no meaningful opinion could be formed (*specify*):

the claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported by the description that no meaningful opinion could be formed.

no international search report has been established for said claims Nos. 10-13

the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form

has not been furnished

does not comply with the standard

the computer readable form

has not been furnished

does not comply with the standard

the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

See Supplemental Box for further details.

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/JP2005/004098

Box No. V <u>Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</u>																			
<p>1. Statement</p> <table> <tr> <td>Novelty (N)</td> <td>Claims <u>1-9, 14</u></td> <td>YES</td> </tr> <tr> <td></td> <td>Claims _____</td> <td>NO</td> </tr> <tr> <td>Inventive step (IS)</td> <td>Claims <u>1-9, 14</u></td> <td>YES</td> </tr> <tr> <td></td> <td>Claims _____</td> <td>NO</td> </tr> <tr> <td>Industrial applicability (IA)</td> <td>Claims <u>1-9, 14</u></td> <td>YES</td> </tr> <tr> <td></td> <td>Claims _____</td> <td>NO</td> </tr> </table>		Novelty (N)	Claims <u>1-9, 14</u>	YES		Claims _____	NO	Inventive step (IS)	Claims <u>1-9, 14</u>	YES		Claims _____	NO	Industrial applicability (IA)	Claims <u>1-9, 14</u>	YES		Claims _____	NO
Novelty (N)	Claims <u>1-9, 14</u>	YES																	
	Claims _____	NO																	
Inventive step (IS)	Claims <u>1-9, 14</u>	YES																	
	Claims _____	NO																	
Industrial applicability (IA)	Claims <u>1-9, 14</u>	YES																	
	Claims _____	NO																	
<p>2. Citations and explanations:</p> <p>&lt;Documents cited in the ISR&gt;</p> <p>Document 1: WO, 2000-003728, A1 (Schering Corp.), 1 August, 2002 (01.08.02)      Document 2: JP, 2003-530325, A (IPF Pharmaceuticals GmbH), 14 October, 2003 (14.10.03)      Document 3: JP, 2003-516324, A (Schering Corp.), 13 May, 2003 (13.05.03)      Document 4: JP, 2003-508388, A (Chemocentryx, Inc.), 4 March, 2003 (04.03.03)      Document 5: JP, 2002-525338, A (Corixa Corp.), 13 August, 2002 (13.08.02)      Document 6: JP, 2002-513388, A (Theodor-Kocher Institute), 8 May, 2002 (08.05.02)      Document 7: ROBLEDO M M et al., Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells., Journal of biological chemistry, 30 November, 2001 (30.11.01), 276 (48), pp. 45098-105</p> <p>&lt;Explanation&gt;</p> <p>The inventions of claims 1-9 and 14 appear to involve an inventive step in view of documents 1-7 cited in the ISR.</p> <p>Documents 1-7 do not describe the idea that CXCR3 inhibitors are effective for the treatment of metastatic and other cancer, and this point cannot easily be conceived even by a person skilled in the art.</p>																			

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/JP2005/004098

Box No. VI Certain documents cited

1. Certain published documents (Rule 43bis.1 and 70.10)

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
JP 2005-132761 A [EX, EY]	26.05.2005	29.10.2003	

2. Non-written disclosures (Rule 43bis.1 and 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2005/004098

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1, 5, 6 and 8 relate to medical compositions to treat cancer which contain, as active ingredients, compounds defined by their desired properties, for example, "a CXCR3 inhibitor", "a CXCR3-mediated signal transduction inhibitor in cancer cells", "a CXCR3 expression inhibitor", "a CXCR3 antagonist and an antibody against a CXCR3 ligand and a fragment thereof having an antigen-binding activity", "a CXCR3 antisense, siRNA and a CXCR3 expression inhibitor", "a mutant of a CXCR3 ligand and a ligand-binding inhibitor." And claims 1, 5, 6 and 8 include all compounds having such properties, but only a very small portion of the claimed compounds are supported by the description in the sense of PCT Article 6, and disclosed in the sense of PCT Article 5.

And for "CXCR3 inhibitor", no scope of compounds having such properties can be specified even when considering the common general technical knowledge at the time of the application. Therefore, claims 1, 5, 6 and 8 do not fulfill the requirement of clarity according to PCT Article 6.